BiotechTube

Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Marginal Zone Lymphoma

Conditions

Marginal Zone Lymphoma

Trial Timeline

Jun 21, 2022 → Jun 30, 2029

NCT ID
NCT05296070

About Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg

Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg is a phase 2 stage product being developed by ADC Therapeutics for Marginal Zone Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05296070. Target conditions include Marginal Zone Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05296070Phase 2Recruiting

Competing Products

10 competing products in Marginal Zone Lymphoma

See all competitors
ProductCompanyStageHype Score
Copanlisib + RituximabCelltrionPhase 2
52
Rituximab + PembrolizumabCelltrionPhase 2
52
Pirtobrutinib + RituximabEli LillyPhase 2
52
EpcoritamabAbbViePhase 2
52
Rituximab + VenetoclaxAbbViePhase 2
52
VAY736 + lenalidomideNovartisPhase 1
33
PI3K inhibitor BKM120 + rituximabNovartisPhase 1
33
ObinutuzumabRochePhase 2
52
UmbralisibTG TherapeuticsPhase 2
49
HMPL-689HUTCHMEDPhase 2
47

Other Products from ADC Therapeutics

Loncastuximab Tesirine + Rituximab + Gemcitabine + OxaliplatinPhase 3
69
Loncastuximab tesirine + RituximabPhase 2
44
Loncastuximab Tesirine + RituximabPhase 2
44
Loncastuximab tesirinePhase 2
44
Loncastuximab Tesirine + RituximabPhase 2
44